News >

European Panel Recommends Against Neratinib for HER2-Positive Breast Cancer

Jason Harris
Published: Friday, Feb 23, 2018

breast cancer
European regulators have recommended against approving a marketing authorization application (MAA) for the use of neratinib (Nerlynx) as extended adjuvant treatment for women with early stage HER2-positive breast cancer.

The rate of dose reductions (7.3% vs 26.4%) and holds (14.6% vs 33.9%) due to diarrhea were lower in the patients who received loperamide. However, the rate of discontinuation due to diarrhea was higher in the loperamide cohort at 20.4% versus 16.8% with neratinib alone.

References

  1. Martin M, Holmes FA, Ejlertsen B, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18:1688-700.
  2. Puma Biotechnology presents interim results of phase II CONTROL Trial of PB272 in extended adjuvant treatment of her2-positive early stage breast cancer at the 2017 AACR Annual Meeting. Posted April 4, 2017. Accessed February 23, 2018. http://bit.ly/2EXiduL.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x